Versant Capital Management, Inc Dyne Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 44 shares of DYN stock, worth $511. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44
Previous 283
84.45%
Holding current value
$511
Previous $3,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
123MCall Options Held
36.5KPut Options Held
16.7K-
Ra Capital Management, L.P. Boston, MA9.71MShares$113 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$110 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$106 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$88.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$85.8 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $602M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...